PHILLIPSBURG, N.J., Nov. 11, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that preliminary data from " ReACT: a Phase 2 Study of Rindopepimut Vaccine (CDX-110) Plus Bevacizumab in Relapsed Glioblastoma", was published in the 2013 abstract supplement to the journal Neuro-Oncology; abstracts were also published online at http://neuro-oncology.oxfordjournals.org/ . Data included in the abstract were as of the time of submission (May 2013) and more comprehensive, updated data from the study will be presented by David Reardon, MD, Clinical Director, Center for Neuro-Oncology, Dana Farber Cancer Center and Associate Professor of Medicine, Harvard Medical School during an oral session on Sunday, November 24 from 10:20 am to 12:00 pm PT at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology held in conjunction with the 18th Annual Meeting of the Society for Neuro-Oncology in San Francisco, CA. As previously disclosed, Celldex will issue a press release in concordance with the presentation on November 24 and will host a conference call to review the data on Monday, November 25 at 8:30 am ET.
- Group 1 - Avastin naive, n= apx. 70, enrollment ongoing—patients randomized to receive either rindopepimut or KLH (administered as a control), each along with Avastin
- Group 2 - Avastin refractory, n= apx. 25, enrollment completed—patients receive rindopepimut plus Avastin in a single treatment arm
- Group 2C (C = Confirmatory) - Avastin refractory expansion, n = apx. 75, enrollment initiated—patients receive rindopepimut plus Avastin in a single treatment arm